168 related articles for article (PubMed ID: 19273791)
1. Retinoblastoma regression patterns following chemoreduction and adjuvant therapy in 557 tumors.
Shields CL; Palamar M; Sharma P; Ramasubramanian A; Leahey A; Meadows AT; Shields JA
Arch Ophthalmol; 2009 Mar; 127(3):282-90. PubMed ID: 19273791
[TBL] [Abstract][Full Text] [Related]
2. [Retinoblastoma regression patterns and results following chemo reduction and adjuvant therapy].
Xue K; Qian J; Yue H; Yuan YF; Zhang R
Zhonghua Yan Ke Za Zhi; 2012 Jul; 48(7):625-30. PubMed ID: 22943868
[TBL] [Abstract][Full Text] [Related]
3. Macular retinoblastoma managed with chemoreduction: analysis of tumor control with or without adjuvant thermotherapy in 68 tumors.
Shields CL; Mashayekhi A; Cater J; Shelil A; Ness S; Meadows AT; Shields JA
Arch Ophthalmol; 2005 Jun; 123(6):765-73. PubMed ID: 15955977
[TBL] [Abstract][Full Text] [Related]
4. Chemoreduction for retinoblastoma. Analysis of tumor control and risks for recurrence in 457 tumors.
Shields CL; Mashayekhi A; Cater J; Shelil A; Meadows AT; Shields JA
Am J Ophthalmol; 2004 Sep; 138(3):329-37. PubMed ID: 15364213
[TBL] [Abstract][Full Text] [Related]
5. Development of new retinoblastomas after 6 cycles of chemoreduction for retinoblastoma in 162 eyes of 106 consecutive patients.
Shields CL; Shelil A; Cater J; Meadows AT; Shields JA
Arch Ophthalmol; 2003 Nov; 121(11):1571-6. PubMed ID: 14609913
[TBL] [Abstract][Full Text] [Related]
6. Regression patterns in treated retinoblastoma with chemotherapy plus focal adjuvant therapy.
Ghassemi F; Rahmanikhah E; Roohipoor R; Karkhaneh R; Faegh A
Pediatr Blood Cancer; 2013 Apr; 60(4):599-604. PubMed ID: 23034769
[TBL] [Abstract][Full Text] [Related]
7. Factors predictive of recurrence of retinal tumors, vitreous seeds, and subretinal seeds following chemoreduction for retinoblastoma.
Shields CL; Honavar SG; Shields JA; Demirci H; Meadows AT; Naduvilath TJ
Arch Ophthalmol; 2002 Apr; 120(4):460-4. PubMed ID: 11934319
[TBL] [Abstract][Full Text] [Related]
8. Chemoreduction plus focal therapy for retinoblastoma: factors predictive of need for treatment with external beam radiotherapy or enucleation.
Shields CL; Honavar SG; Meadows AT; Shields JA; Demirci H; Singh A; Friedman DL; Naduvilath TJ
Am J Ophthalmol; 2002 May; 133(5):657-64. PubMed ID: 11992863
[TBL] [Abstract][Full Text] [Related]
9. Histopathologic findings in eyes with retinoblastoma treated only with chemoreduction.
Demirci H; Eagle RC; Shields CL; Shields JA
Arch Ophthalmol; 2003 Aug; 121(8):1125-31. PubMed ID: 12912690
[TBL] [Abstract][Full Text] [Related]
10. Chemoreduction for retinoblastoma: analysis of tumor control and risks for recurrence in 457 tumors.
Shields CL; Mashayekhi A; Cater J; Shelil A; Meadows AT; Shields JA
Trans Am Ophthalmol Soc; 2004; 102():35-44; discussion 44-5. PubMed ID: 15747743
[TBL] [Abstract][Full Text] [Related]
11. Evolution in regression patterns following chemoreduction for retinoblastoma.
Palamar M; Thangappan A; Shields CL
Arch Ophthalmol; 2011 Jun; 129(6):727-30. PubMed ID: 21670339
[TBL] [Abstract][Full Text] [Related]
12. The International Classification of Retinoblastoma predicts chemoreduction success.
Shields CL; Mashayekhi A; Au AK; Czyz C; Leahey A; Meadows AT; Shields JA
Ophthalmology; 2006 Dec; 113(12):2276-80. PubMed ID: 16996605
[TBL] [Abstract][Full Text] [Related]
13. Causes of chemoreduction failure in retinoblastoma and analysis of associated factors leading to eventual treatment with external beam radiotherapy and enucleation.
Gündüz K; Günalp I; Yalçindağ N; Unal E; Taçyildiz N; Erden E; Geyik PO
Ophthalmology; 2004 Oct; 111(10):1917-24. PubMed ID: 15465557
[TBL] [Abstract][Full Text] [Related]
14. What is the best treatment for retinoblastoma?
Harbour JW
Am J Ophthalmol; 2004 Sep; 138(3):471-3. PubMed ID: 15364232
[No Abstract] [Full Text] [Related]
15. Chemoreduction for group E retinoblastoma: comparison of chemoreduction alone versus chemoreduction plus low-dose external radiotherapy in 76 eyes.
Shields CL; Ramasubramanian A; Thangappan A; Hartzell K; Leahey A; Meadows AT; Shields JA
Ophthalmology; 2009 Mar; 116(3):544-551.e1. PubMed ID: 19157557
[TBL] [Abstract][Full Text] [Related]
16. Chemoreduction for unilateral retinoblastoma.
Shields CL; Honavar SG; Meadows AT; Shields JA; Demirci H; Naduvilath TJ
Arch Ophthalmol; 2002 Dec; 120(12):1653-8. PubMed ID: 12470138
[TBL] [Abstract][Full Text] [Related]
17. Clinical efficacy and prognostic factors of chemoreduction combined with topical treatment for advanced intraocular retinoblastoma.
Liu Y; Zhang X; Liu F; Wang KL
Asian Pac J Cancer Prev; 2014; 15(18):7805-9. PubMed ID: 25292067
[TBL] [Abstract][Full Text] [Related]
18. Retinocytoma shows lack of response to chemoreduction.
Chung J; Turaka K; Shields CL
J Pediatr Ophthalmol Strabismus; 2010 Dec; 47 Online():e1-3. PubMed ID: 21175116
[TBL] [Abstract][Full Text] [Related]
19. Tumor Regression Patterns in Retinoblastoma.
Zafar SN; Siddiqui SN; Zaheer N
J Coll Physicians Surg Pak; 2016 Nov; 26(11):896-899. PubMed ID: 27981923
[TBL] [Abstract][Full Text] [Related]
20. Intravenous chemoreduction or intra-arterial chemotherapy for cavitary retinoblastoma: long-term results.
Rojanaporn D; Kaliki S; Bianciotto CG; Iturralde JC; Say EA; Shields CL
Arch Ophthalmol; 2012 May; 130(5):585-90. PubMed ID: 22652844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
